An interventional study of Implantation of the ArtiFascia® and Implantation of other commercial suturable dural substitute in Dural Tear and Cerebrospinal Fluid Leak, sponsored by Nurami Medical Ltd. Completed at 9 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-08-19.
Sponsored by Nurami Medical Ltd · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of this study was to evaluate the safety and effectiveness of ArtiFascia® in comparison with commercially available dural substitutes in subjects requiring Dural repair following neurosurgery.
Subjects with planned cranial neurosurgery participated in this study. During the surgery the dura is likely to be cut and damaged. A damaged dura can cause a leakage of brain fluids (cerebrospinal fluid [CSF] leakage) and increase the risk of infections. The damaged dura can be fixed with dural patch like ArtiFascia®. ArtiFascia® is a bioabsorbable medical synthetic dural replacement that aids in the regeneration of a new dura. Furthermore, it incorporates a sealing layer capable of minimizing CSF leakage and infection.
A Prospective, randomized, controlled multi-center study of ArtiFascia® Dural repair patch compared with commercially available dural substitutes- NEOART Study.
The dura mater is a fibrous connective tissue that surrounds the nervous system (brain and spinal cord) and provides a mechanical barrier that contains the cerebrospinal fluid (CSF). The dura mater may be damaged as a result of trauma or planned surgery. When dural defects cannot be repaired by primary closure, a dural substitute must be utilized in order to reduce CSF leakage.
There are devices that have been used as dural substitutes. Among the devices that are based on natural raw materials, collagen-based matrices are widely used. Although collagen was proven to be biocompatible, using collagen-based materials still possess several limitations such as CSF leaks. Synthetic dural substitutes are also used to repair dura mater. The most widely used raw-material for these synthetic products are polyesters - resorbable and biocompatible polymers. There are several dural substitutes based on synthetic polyesters that were successfully tested pre-clinically as well as in human studies.
Sponsor of this study has developed the ArtiFascia®. ArtiFascia® is a polymeric synthetic dural substitute that is absorbed by the body.
Before the study, all subjects underwent neurological assessment. Only subjects that were found to be suitable to participate in the study, and agree to participate, were randomly allocated into one of the following groups:
The Sponsor was blinded to treatment. The subjects underwent the planned surgery and at the end the investigator used ArtiFascia® patch or standard dural substitute to repair the damaged Dura. ArtiFascia® graft was placed in areas where the native dural layer was damaged or missing. ArtiFascia® was applied via a routine and well-known procedure, using a suturing technique. After implantation, the porous fibrous structure of ArtiFascia® provides a scaffold, which enables infiltration of fibroblasts and cells from the intact tissue, ultimately replacing damaged dural tissue. The patch is expected to resorb within a few months and to be replaced by the native tissue with complete dural closure.
During the surgery and until subject's release from the hospital the subject's health was closely monitored. Before the discharge subjects underwent neurological examination. Subjects had been followed up at 4-6 weeks and at 6 months post surgery.
At each follow up visit physical and neurological examinations were performed. Radiographic Evaluation (Magnetic Resonance Imaging) was performed at 6 months post operation.
A total of 92 subjects from 7 sites in Europe were enrolled and implanted with test or control device.
The primary endpoint was achieved when the final study subject has completed a 6-months follow-up.
41 studies on the registry are indexed under Cerebrospinal Fluid Leak; 9 are open to participants now.
This study's enrollment of 92 is above the median of 74 across 24 interventional studies indexed under Cerebrospinal Fluid Leak.
Browse Cerebrospinal Fluid Leak studies →Nurami Medical Ltd is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Procedure was performed under general anesthesia. The subjects underwent the planned surgery. At the end of the surgery, the investigator used the ArtiFascia® patch. Implantation of the ArtiFascia® was according to clinical discretion of the physician, and in compliance with ArtiFascia® instructions for use. Post operation the subject stayed at the hospital according to site standards and physician discretion.
Device: Implantation of the ArtiFascia®
Same procedure as for the treatment arm but using a commercial suturable dural substitute. Implantation of the commercial suturable dural substitute was according to clinical discretion of the physician, and in compliance with each specific device instructions for use.
Device: Implantation of other commercial suturable dural substitute
Following are the general instructions for use for the ArtiFascia®: * Cut the ArtiFascia® to the required shape under aseptic conditions * Apply ArtiFascia® to the damaged area * Suture the ArtiFascia® in place * Suture bites should be taken 2-3 millimeters from the edges of the implant. Either a running suture or interrupted stitches' technique may be used, depending on clinical conditions or surgeon's decision. Important Note: If clinically possible, do not use dural adhesive or sealants as it is an uncontrolled variable, that can influence the results.
Implantation of the commercial suturable dural substitute will be according to clinical discretion of the physician, and in compliance with each specific device instructions for use. Detailed instructions are in the instructions for use
Absence of Cerebrospinal Fluid Fistula (Drainage From Wound or Sinus) and Pseudo-meningocele Within 6 Months Post-operative as Evaluated by MRI Imaging.
The primary end point will be assessed by evaluating the absence of cerebrospinal fluid fistula (drainage from wound or sinus) and pseudo-meningocele post-operative as evaluated by MRI imaging and physical examination of the surgical site.
Time frame: 6 month.
Wound Healing Assessment
Clean and/or fully healed vs. Infected. Evaluation of wound will be done in physical examination: clean and/or fully healed/ infected. If wound is infected additional assessment of mild/moderate/severe will be done.
Time frame: 6 month follow-up
Device Handling Characteristics as Reported by a User Experience Questionnaire
The following scoring system was used for the evaluation: 1\) Device ease of use, suturing and cutting were evaluated on a scale of 1=Easy to 5=Difficult. 2) Device strength and seal quality (during implantation) were scored on scale of 1=Low to 5=High.
Time frame: On the day of the surgical procedure
Radiological Imaging at 6 Months for Additional Findings at Implant Site
The rate of each of the following: Extracerebral fluid accumulation, pseudomeningocele, adhesion formation, brain edema adjacent to device implant site, abnormal thickening at implantation site and new membrane (scar) formation.
Time frame: 6 month follow-up
The clinical trial was performed in 8 European medical centers (Poland, Czech Republic, Spain and Belgium) and in 1 Israeli medical center. Subjects were enrolled from January 2020 to January 2022.
| Milestone | Treatment Arm- ArtiFascia® Patch | Control-Other Commercial Suturable Dural Substitute |
|---|---|---|
| Started | 63 | 29 |
| Treated | 62 | 27 |
| Completed | 58 | 27 |
| Not completed | 5 | 2 |
The primary end point will be assessed by evaluating the absence of cerebrospinal fluid fistula (drainage from wound or sinus) and pseudo-meningocele post-operative as evaluated by MRI imaging and physical examination of the surgical site.
| Participants | Control-Other Commercial Suturable Dural Substitute | Treatment Arm-ArtiFascia® Graft |
|---|---|---|
| Presence of cerebrospinal fluid fistula and Pseudomeningocele | 0 | 0 |
| No events of cerebrospinal fluid fistula and Pseudomeningocele | 27 | 58 |
Clean and/or fully healed vs. Infected. Evaluation of wound will be done in physical examination: clean and/or fully healed/ infected. If wound is infected additional assessment of mild/moderate/severe will be done.
Results for this outcome have not been posted.
The following scoring system was used for the evaluation: 1\) Device ease of use, suturing and cutting were evaluated on a scale of 1=Easy to 5=Difficult. 2) Device strength and seal quality (during implantation) were scored on scale of 1=Low to 5=High.
Results for this outcome have not been posted.
The rate of each of the following: Extracerebral fluid accumulation, pseudomeningocele, adhesion formation, brain edema adjacent to device implant site, abnormal thickening at implantation site and new membrane (scar) formation.
| Participants | Treatment Arm-ArtiFascia® Graft | Control-Other Commercial Suturable Dural Substitute |
|---|---|---|
| Present measures | 1 | 3 |
| No findings presence | 57 | 24 |
Collected over 2.5 years. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment Arm-ArtiFascia® Graft | 1/63 (1.6%) | 9/63 (14.3%) | 26/63 (41.3%) |
| Control-Other Commercial Suturable Dural Substitute | 0/29 (0%) | 3/29 (10.3%) | 15/29 (51.7%) |
| Event | Treatment Arm-ArtiFascia® Graft | Control-Other Commercial Suturable Dural Substitute |
|---|---|---|
| Light chain diseaseNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/63 | 1/29 |
| SeizureNervous system disorders | 0/63 | 1/29 |
| VasospasmVascular disorders | 0/63 | 1/29 |
| Facial paresisNervous system disorders | 1/63 | 0/29 |
| B-cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/63 | 0/29 |
| Neoplasm of orbitNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/63 | 0/29 |
| Cerebral haemorrhageNervous system disorders | 1/63 | 0/29 |
| Extradural abscessInfections and infestations | 1/63 | 0/29 |
| PneumoniaInfections and infestations | 1/63 | 0/29 |
| Cardio-respiratory arrestCardiac disorders | 1/63 | 0/29 |
| Event | Treatment Arm-ArtiFascia® Graft | Control-Other Commercial Suturable Dural Substitute |
|---|---|---|
| EpilepsyNervous system disorders | 3/63 | 0/29 |
| Facial paresisNervous system disorders | 0/63 | 1/29 |
| Taste disorderNervous system disorders | 0/63 | 1/29 |
| Eye swellingEye disorders | 0/63 | 1/29 |
| Cerebrospinal fluid leakageNervous system disorders | 0/63 | 1/29 |
| InflammationGeneral disorders | 0/63 | 1/29 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 0/63 | 1/29 |
| HeadacheNervous system disorders | 0/63 | 1/29 |
| EpilepsyNervous system disorders | 0/63 | 1/29 |
| HaemorrhageVascular disorders | 0/63 | 1/29 |
Men and women between the ages of 18-75 scheduled for an elective cranial surgery that requires dural repair, meet all the inclusion and none of the exclusion criteria.
| Age, Categorical(Participants) | Treatment Arm-ArtiFascia® Graft | Control-Other Commercial Suturable Dural Substitute | Total |
|---|---|---|---|
| <=18 years | 0 | 1 | 1 |
| Between 18 and 65 years | 48 | 23 | 71 |
| >=65 years | 15 | 5 | 20 |
| Sex: Female, Male(Participants) | Treatment Arm-ArtiFascia® Graft | Control-Other Commercial Suturable Dural Substitute | Total |
|---|---|---|---|
| Female | 43 | 21 | 64 |
| Male | 20 | 8 | 28 |
| Ethnicity (NIH/OMB)(Participants) | Treatment Arm-ArtiFascia® Graft | Control-Other Commercial Suturable Dural Substitute | Total |
|---|---|---|---|
| Hispanic or Latino | 14 | 4 | 18 |
| Not Hispanic or Latino | 49 | 25 | 74 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Treatment Arm-ArtiFascia® Graft | Control-Other Commercial Suturable Dural Substitute | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 62 | 29 | 91 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Treatment Arm-ArtiFascia® Graft | Control-Other Commercial Suturable Dural Substitute | Total |
|---|---|---|---|
| Belgium | 3 | 2 | 5 |
| Czechia | 19 | 9 | 28 |
| Poland | 28 | 12 | 40 |
| Spain | 13 | 6 | 19 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2020 to primary completion in Nov 2022, 33 months.
Results were first posted in Aug 2025, 2 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nurami Medical Ltd